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Response to pharmacological treatment is variable among individuals. Some patients 
respond favorably to a drug while others develop adverse reactions. Early investigations 
showed evidence of variation in genes that code for drug receptors, drug transporters, and 
drug metabolizing enzymes; and pharmacogenetics appeared as the science that studies the 
relationship between drug response and genetic variation.  
Thiazide diuretics are the recommended first-line monotherapy for hypertension (i.e. 
SBP>140 or DBP>90). Even so, diuretics are associated with adverse metabolic side effects, 
such as hyperglycemia, which increase the risk of developing type 2 diabetes. Published 
approaches testing variation in candidate genes (e.g. the renin-angiotensin-aldosteron system 
(RAAS) and salt–sensitivity genes) have met with only limited success.   
We conducted the first genome wide association study to identify genes influencing 
hyperglycemia as an adverse effect of thiazide diuretics in non-Hispanic White hypertensive 
patients participating in the Genetic Epidemiology of Responses to Antihypertensives 
(GERA) and Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) clinical 
trials. No SNP reached the a priori defined threshold of statistical significance (p<5x10
-8
). 
We detected 50 SNPs in 9 genomic regions with suggestive p-values (p<1x10
-5
). Two of 
them, rs6870564 (p-value=3.28 X 10
-6
) and rs7702121 (p-value=5.09 X 10
-6
), were located 
 v 
 
close to biologic candidate genes, MYO and MGAT1, and one SNP in a genomic region in 
chromosome 6, rs7762018 (p-value=4.59 X 10
-6
) has been previously related to Insulin-
Dependent Diabetes Mellitus (IDDM8).  
I conclude that 1) there are unlikely to be common SNPs with large effects on the 
adverse metabolic effects to hydrochlorothiazide treatment and 2) larger sample sizes are 
needed for pharmacogenetic studies of inter-individual variation in response to commonly 
prescribed medication. 
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Introduction 
 
Hypertension is a major risk factor for stroke, cardiovascular and kidney diseases
1
. 
Hydrochlorothiazide (HCTZ) is a widely used diuretic recommended for part of the initial 
treatment of hypertension
2
. It is also one of the first drugs documented to improve clinical 
outcomes in patients with hypertension. However its ability to over-stimulate the RAAS 
(renin-angiotensin-aldosterone system) and to produce a variety of Adverse Metabolic 
Effects (AME) is well-known. These AMEs can be classified into two main types: 
electrolyte defects (hypokalemia
3-7
, hyponatremia
8-10
, and hyperuricemia
11, 12
) and metabolic 
abnormalities (hyperglycemia
3, 13-15
 and dyslipidemia
15-18
).  Among the metabolic 
abnormalities, hyperglycemia is particularly important because of the possibility of leading 
to a diagnosis of diabetes. A meta-analysis of 22 different clinical trials including 143,153 
patients
19
 showed that the odds ratio for incident of diabetes in antihypertensive clinical 
trials for HCTZ was 1.3. Although the risk is clinically significant, it is not observed in all 
patients. None the less, some clinicians suggest that the prescription of HCTZ should be 
avoided because of this adverse outcome
20, 21
 
 
The precise mechanism by which HZCT influences glucose and triglyceride levels is not 
well understood. Three possible mechanisms have been proposed. The first possible 
mechanism suggests that inhibition of the renal sodium chloride channel by HZCT increases 
sodium and potassium excretion in urine
16
. The second states that the RAAS pathway is 
activated due to volume depletion, leading to increased aldosterone and potassium 
secretion
16
. The hypotheses conclude that hypokalemia induces higher proinsulin over 
 2 
 
insulin secretion. Proinsulin is less active than insulin leading to an increased concentration 
of blood glucose
2
. The third possible mechanism suggests that increases in hepatic fat 
content decreases insulin sensitivity which produces hyperglycemia and most patients taking 
HCTZ develop higher hepatic fat content
22
. 
 
One way to distinguish among these competing hypotheses, is to identify genetic variations 
that are predictive of inter-individual variation in the AME of HCTZ treatment. In previous 
targeted candidate gene studies, two loci have been reported to predict thiazide-induced 
hyperglycemia
23: the potassium inwardly rectifying channel (KCNJ1) and the β-2 adrenergic 
receptor (ADRB2). However, no replication of these findings has been reported.  An 
alternative approach to a candidate gene study is to query every gene and genomic region 
using a genome-wide association approach. In this thesis, I seek to identify genetic 
associations of HCTZ-induced change in plasma glucose that are replicated among two 
independent clinical trials in non-Hispanic whites, the Genetic Epidemiology of Responses 
to Antihypertensives (GERA) and Pharmacogenomic Evaluation of Antihypertensive 
Responses (PEAR).  
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Materials and Methods. 
 
1. Study population 
 
The phenotype and genotype data were collected from The Genetic Epidemiology of 
Responses to Antihypertensives (GERA) study and The Pharmacogenomic Evaluation of 
Antihypertensive Responses (PEAR) study. Both studies have been described previously 
24, 
25
. 
In the GERA study, African-Americans and non-Hispanic Whites with essential 
hypertension were recruited at Emory University in Atlanta, GA, and at the Mayo Clinic in 
Rochester, MN, respectively. Essential hypertension was defined as blood pressure levels 
greater than 140/90 mmHg in the absence of a single known cause, or current use of 
prescription antihypertensive medications. Subjects with the following characteristics were 
not enrolled in the GERA study: allergy to hydrochlorothiazide; inability to discontinue 
antihypertensive medication, non-steroidal anti-inflammatory medication 
(aspirin>325mg/d), liver disease, renal disease, diabetes mellitus (FBG > 140mg/dl or use of 
hypoglycemic medications), or use of oral contraceptives. The institutional review boards of 
the Mayo Clinic and Emory University approved the GERA study. The protocol for the 
GERA study was as follows: a wash-out period of at least 4 weeks was done in order to 
remove the effects of previous blood pressure medication. If during the wash out period an 
individual’s blood pressure was > 180/110 mmHg, they were withdrawn from the study for 
safety reasons; if at the end of the wash-out period the diastolic blood pressure (DBP) was 
<90mmHg, they were withdrawn from the study. Blood pressure was measured and blood 
samples were obtained for baseline biochemical measurements from the remaining 
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individuals. Qualifying individuals were given hydrochlorothiazide (25mg orally once daily) 
for 4 weeks. Subjects were asked to keep dietary sodium intake at approximately 
2mmol/kg/day. A 24 hour urine sodium excretion measurement and food recall diaries were 
checked for dietary compliance. At the end of the 4 week diuretic treatment period, blood 
pressure was measured and blood samples were again obtained for biochemical 
measurements. In order to measure blood pressure at baseline and after diuretic treatment, 
individuals were in the seated position for 5 minutes before the reading was done by a 
trained nurse using a mercury sphygmomanometer. All blood collections were in the 
morning after 8 hours of fasting.  For this project, we defined response to 
hydrochlorothiazide as the difference between the measurements collected after the 4 weeks 
of diuretic treatment and the baseline measurement. 
In the PEAR study, any race-ethnicity gender combination from age 17 to 65 years old 
with mild to moderate essential hypertension was recruited. Subjects were enrolled from 
Gainesville, Fl, Atlanta, GA, and Rochester, MN. All participants were newly diagnosed 
hypertensive, untreated hypertensive or treated hypertensive with less than three 
antihypertensive drugs. The exclusion criteria were: secondary hypertension, known 
cardiovascular disease, diabetes mellitus (type I or II) or FBG > 126mg/dL, primary renal 
disease, the presence of Raynaud syndrome (constriction of the small arteries in fingers and 
toes due to cold weather or emotional state), pregnancy or lactation, abnormal liver enzymes 
(AST, ALT or alkaline phosphatase  > 2.5 times the upper limit of normal). The protocol of 
the study was as follows: a wash out period of at least two weeks was observed in order to 
remove the effects of previous blood pressure medication from the participants.  A period of 
two weeks was used because in the GERA study the study investigator observed that stable 
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blood pressure rises were already obtained by this time. If at the end of the wash out period 
the average seated home DBP> 85mmHg and the home systolic blood pressure (SBP) < 
180mmHg the individuals were enrolled into the randomized phase. All biological samples 
(blood and urine) were collected in the fasting state. As soon as the baseline studies were 
completed, the individuals were randomized to hydrochlorothiazide (diuretic drug-12.5mg 
orally once daily) or atenolol (β-blocker drug-50mg orally once daily). For this thesis 
research, I used only the patients randomized to the diuretic drug-arm from the PEAR study 
referred hereafter as PEAR monotherapy. If after 3 weeks the individual’s average home and 
clinic blood pressure was > 120/70mmHg, then the dose of hydrochlorothiazide was 
increased (25mg orally once daily). All participants were examined in clinic every 10-21 
days throughout the study.  
For the purpose of this thesis research only non-Hispanic whites from GERA and PEAR 
were included.  
2. Phenotype and Genotype data 
 
In the GERA study, plasma glucose concentrations were determined by automated 
spectrophotometric methods implemented on an IL Monarch Chemistry system 760 
(Instrumentation Laboratories, Lexington, MA, USA). In the PEAR study, these methods 
were implemented on a  Hitachi 911 Chemistry Analyzer (Roche Diagnostics, Indianapolis, 
IN, USA). In both studies, plasma glucose concentrations were measured at the end of the 
drug-free period (baseline) and at the end of the hydrochlorothiazide period (final). Glucose 
response to hydrochlorothiazide was defined as the difference between the levels at the final 
and the baseline visits.  
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In the GERA study, a subset of individuals was genotyped using the GeneChip Human 
Mapping 500K Array, (Affymetrics, Santa Clara California, USA). The subset was selected 
based on the upper and lower tertile of DBP response. First, blood pressure measurements 
were adjusted for age and baseline DBP levels. Then, cases were defined as individuals from 
each race gender subgroup who had a DBP in the highest tertile and controls were defined as 
individuals from each race gender subgroup, who had a DBP in the lowest tertile. Each 
group had equal numbers of African American and non-Hispanics Whites.  
PEAR participants were genotyped for the Illumina HumanOmni1-Quad (Illumina, San 
Diego, California, USA) using standard procedures. As part of routine quality control, SNP 
with minor allele frequency (MAF) <1%, call rates <95%, Hardy-Weinberg equilibrium p-
values ≥ 10-5 and individuals with more than 10% missing genotype were removed from the 
analysis. 
3. Statistical analysis 
 
The software MACH
26
 (www.sph.umich.edu/csg/abecasis/MACH/download ) was used 
for imputating the approximate 2.5 million HapMap SNPs using the reference panel for the 
European-Americans the Phase II CEU panel. Imputation results were filtered if the squared 
correlation between imputed and true genotypes (RSQ_HAT) were below the threshold of 
0.3 and MAF ≤ 0.05. MACH generated a file with the highest posterior probabilities 
(i.e.dosage) at each imputed SNP which was used in the analysis.  
To avoid the possibility of spurious association as the result of population substructure
27, 
28
, Principal Component Scores (PCS) were used as covariates in the analysis. These PCS  
were  obtained using the EIGENSTRAT
28
 software 
(genepath.med.harvard.edu/~reich/EIGENSTRAT.htm). 
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Linear regression was used to evaluate the association between each SNP and glucose 
response to hydrochlorothiazide. The variables sex, age, BMI, baseline glucose, and the first 
two principal component scores were used as covariates. A one degree of freedom additive 
model was applied. The analysis was performed using ProbABEL
29
. These genome-wide 
analyses were done separately for each study, and the results were subsequently meta-
analyzed using a fixed effect model
30 
with the inverse of the variance of the study-specific β-
estimates to weight the contribution of each study. Meta-analysis was done using METAL 
(www.sph.umich.edu/csg/abecasis/metal). For the genome-wide analysis and the meta-
analysis, the definition of statistical significance was taken to be p<5x10
-8
 and the direction 
of effect (β) had to be the same in both studies. This Bonferroni-like correction reduces the 
probability of type I errors (false positives) but increases the probability of type II errors 
(false negatives). A statistically suggestive p value was defined as p<1x10
-5
, and was used in 
order to avoid the rejection of possible true positive associations. 
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Results 
 
Characteristics of the study participants at baseline and after treatment are presented 
in Table 1A and Table 1B. The numbers of eligible participants in GERA and PEAR 
monotherapy were 196 and 229, respectively. In both studies, the percentage of male 
participants was higher than female participants (GERA 57.1% and PEAR 59.83%). The 
average age of the participants was almost the same in both studies (GERA 48.5 years and 
PEAR 49.97 years), as well as the average BMI values (GERA 31.3 and PEAR 30.3). In 
both studies, SBP was reduced by approximately 10mmHg, and DBP by approximately 
5mmHg in response to HCTZ treatment. In the GERA study, these average blood pressure 
responses should not be over-interpreted because of the design of the genotyping sub study 
(see methods). The average plasma glucose and plasma cholesterol levels increased 
significantly after treatment with HCTZ in both studies (P<.0001). The average triglyceride 
response was more pronounced in the GERA study compared to the PEAR study. 
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Variables 
GERA: Non-Hispanic Whites 
p 
baseline Post-treatment 
Total 196 
57.1 
48.5±7.3 
31.3±5.6 
 
Gender(%men) 
Age(y) 
Body mass index(BMI) 
Plasma Glucose(mg/dL) 92.4±12.5 95.1±13.2 <.0001 
Total Cholesterol(mg/dL) 187.8±31.2 194.85±34.1 <.0001 
Plasma triglyceride(mg/dL) 184.3±97.6 213.98±164.45 <.0001 
Systolic blood 
pressure(mmHg) 
142.6±12.6 131.7±13.5 <.0001 
Diastolic blood 
pressure(mmHg) 
95±5.7 89.4±9.2 <.0001 
A 
 
Variables 
PEAR: Non-Hispanic Whites 
p 
baseline Post-treatment 
Total 229 
59.83 
49.97±9.4 
30.33±4.9 
 
Gender(%men)  
Age(y)  
Body mass index(BMI)  
Plasma Glucose(mg/dL) 92.8±12.23 94.2±12.89 <.0001 
Total Cholesterol(mg/dL) 196.8±34.68 204.02±38.09 <.0001 
Plasma triglyceride(mg/dL) 149.55±100.9 160.92±122.64 0.03 
Systolic blood 
pressure(mmHg) 
151.8±13.14 141.42±14.43 <.0001 
Diastolic blood 
pressure(mmHg) 
97.9±5.8 93.2±8.6 <.0001 
B 
Table 1: (A) GERA sample characteristics measured at baseline and after 
hydrochlorothiazide treatment. (B) PEAR sample characteristics measured at baseline and 
after hydrochlorothiazide treatment 
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Figure 1 and Figure 2 show the distribution of inter-individual variation in plasma 
glucose response to HCTZ for GERA and PEAR respectively. Figure 1 A shows all of the 
available data, and Figure 1 B shows the distribution after removing individuals whose 
glucose response was beyond three standard deviations from the mean. The final GERA data 
consisted of 193 participants with mean and standard deviation for the change in plasma 
glucose of 3.04±7.55 and a skewness value of 0.697 and a kurtosis of 3.589. Figure 2 A 
presents the distribution of change in glucose from the PEAR study after removing 
participants with missing data (3 subjects). The distribution in Figure 2 B was generated 
after removing individuals over three standard deviations from the mean. These are the 
PEAR data values that were used in the analysis:  220 participants with a mean and standard 
deviation for the change in plasma glucose of 1.44±8.94, and a skewness and kurtosis value 
of 0.007 and 3.328, respectively. 
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(A) 
 
(B) 
Figure 1: Interindividual variation of glucose response to hydrochlorothiazide in the GERA study. 
(A) Glucose distribution before removing phenotypic values over three standard deviations from the 
mean. (B) Actual glucose distribution used in our GWAS analysis. 
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(A) 
 
 
(B) 
Figure 2: Interindividual variation of glucose response to hydrochlorothiazide in the PEAR study. 
(A) Glucose distribution before removing phenotypic values three standard deviations from the 
mean. (B) Actual glucose distribution used in our GWAS analysis.  
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After quality control and imputation (see details in the Materials and Methods), there 
were a total of 2,124,464 SNPs to be analyzed in a sample of 193 non-Hispanics whites in 
GERA. In PEAR, the total number of SNPs was 2,182,834 in 220 non-Hispanics whites. 
The genome-wide association analysis results for GERA and PEAR are presented as 
Manhattan plots in Figure 3 and Figure 4, respectively. No single SNP reached the a priori 
genome-wide threshold of significance. The most significant SNPs were located on 
chromosome 10 at position 10q22-q23 (rs12784681 p-value: 2.522E-6) in GERA and on 
chromosome 6 at position 6q27 (rs9456068 p-value: 1.924E-6) in PEAR.  
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Figure 3: Manhattan plot of P values for SNP association to glucose response to 
hydrochlorothiazide in the GERA study. Observed p values versus chromosome location; 
the circle shows the top signal SNP rs12784681 (p=2.522 x 10
-6
). 
 
 
 
 
 
 
 
 
 
rs12784681 
p-value: 2.522E-6 
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Figure 4: Manhattan plot of P values for SNP association to glucose response to 
hydrochlorothiazide in the PEAR study. Observed p values versus chromosome location; the 
circle shows the top signal SNP rs9456068 (p=1.924 x 10
-6
). 
 
 
 
 
 
 
 
rs9456068 
p-value: 1.924E-6 
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Next, a fixed effects meta-analysis combining β estimates from the two GWAS scans 
(N=413 non-Hispanic whites, 2095294 SNPs) was carried out, and the results are shown in 
Figure 5. No single SNP reached the genome-wide significance threshold, but 50 SNPs in 9 
regions (supplementary Table) reached our definition of suggestive significance (p-value≤ 1 
X 10
-5
) with the same direction of effects between GERA and PEAR).  
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Figure 5: Manhattan plot showing significant association of all SNP in the meta-analysis 
with glucose response to hydrochlorothiazide. Observed p values versus chromosome 
location; the circle shows the top signal SNP rs10989824 (p=3.06 X 10
-6
).    
 
 
 
 
 
 
 
 
 
 
rs10989824 
p-value: 3.06e-06 
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Out of these 50 SNPs in the 9 genomic regions, 12 were chosen as representative of each 
region due to their lowest p-values and high LD with the other SNPs in the same region. 
These SNP are shown in Table 2. The top SNP was located in region I, on chromosome 9. 
The top SNP, rs10989824 (p= 3.06 X 10
-6) has a β value indicating that with the presence of 
each minor allele (T) the change in glucose levels is increased by 5.98 mg/dL. Twenty-two 
other SNPs in high LD with rs10989824, are located in the same region (Supplementary 
Table 3 and Figure 6). The closest gene in this region is the Glutamate [NMDA] receptor 
subunit 3A (GRIN3A) which has been suggested to be involved in the development of 
synaptic elements by modulating NMDA receptor activity
31
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    GERA PEAR Meta-analysis 
SNP chr 
minor 
alleles 
MA
Fa 
beta s.e. 
Pvalue
b beta s.e. Pvalue
b beta s.e. Pvalue bc 
rs10989824 9 T 0.06 -6.91 1.68 4.1e-5 -4.69 1.97 1.7e-2 -5.98 1.28 3.06e-6 
rs427576 16 G 0.44 -2.99 0.78 1.4e-4 -2.25 0.82 5.9e-3 -2.63 0.57 3.25e-6 
rs6870564 5 A 0.13 4.54 1.08 2.7e-5 2.87 1.29 2.6e-2 3.85 0.83 3.28e-6 
rs1669070 2 T 0.40 -2.43 1.09 2.4e-2 -3.38 0.82 3.9e-5 -3.03 0.66 3.82e-6 
rs11077614 17 G 0.49 -3.05 1.25 1.3e-2 -3.25 0.83 9.5e-5 -3.19 0.69 4.12e-6 
rs7762018 6 A 0.13 2.39 1.17 3.8e-2 4.88 1.11 1.2e-5 3.70 0.81 4.59e-6 
rs7702121 5 A 0.14 -3.59 1.16 1.8e-3 -3.98 1.18 7.6-e4 -3.78 1.28 5.09e-6 
rs2114997 5 A 0.43 -2.12 0.75 4.0e-3 -2.93 0.81 2.8e-4 -2.49 0.55 5.25e-6 
rs1551678 10 C 0.37 2.68 0.82 1.0e-3 2.66 0.86 1.9e-3 2.67 0.59 6.91e-6 
rs1974942 4 A 0.11 -5.97 1.94 1.9e-3 -4.62 1.42 1.1e-3 -5.09 1.14 8.69e-6 
rs890749 5 C 0.19 -2.74 1.01 6.1e-3 -3.70 1.03 3.4e-4 -3.21 0.72 8.81e-6 
rs7130701 11 A 0.21 -3.08 0.93 8.5e-4 -3.02 1.02 3.1e-3 -3.05 0.67 8.84e-6 
 
Table 2: SNPs showing association with glucose response to hydrochlorothiazide in meta-
analysis. 
a
Minor allele frequency among the combined sample of GERA and PEAR.  
b
P 
values are based on a linear regression adjusted for sex, age, BMI, baseline glucose and the 
two first principal components of genetic variation for each study. 
c
P values are calculated 
using inverse-variance meta-analysis. 
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Region II, on chromosome 16 contains the second highest SNP with suggestive 
associations with changes in glucose due to HCTZ therapy. The SNP rs427576 (pvalue=3.25 
X 10
-6
) along with 2 other SNPs were located in a genomic region without well-annotated 
genes as shown in Figure 7. The SNP rs6870564 (pvalue=3.28 X 10
-6
) in region III-A, on 
chromosome 5 (Figure 8) is the third most significant region associated with change in 
glucose levels in response to HCTZ therapy. The region contains the MYO10 which is 
related to the myosin heavy chain (MCH) genes. This gene was linked to the pathogenesis of 
type II diabetes
32
. 
The sixth most significantly associated SNP rs7762018 (pvalue=4.59 X 10
-6
), was in 
genomic region VI on chromosome 6, along with 4 other SNPs (rs6923339, rs6941766, 
rs6904601, rs4716942, rs1127489). This chromosomal location, 6q27 (Figure 9), was 
previously reported in a Genome-Wide Meta-Analysis as associated with Type I Diabetes
33
. 
In region III-B (Figure 10), the MGAT1 gene, which was close to the SNP rs7702121 
(pvalue=5.09 X 10
-6
), was associated with BMI, body weight and fatty acid metabolism
34, 35
. 
Figure 11 and Figure 12 show regional plots of the rest of the genomic regions: 
region III-C and III-D were located on chromosome 5, region IV on chromosome 2, region 
V on chromosome 17, region VII on chromosome 10, region VIII on chromosome 4, and 
region IX on chromosome 11. Genes found in these regions are listed in Table 3 
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Gene Symbol 
Ferritin mitochondrial FTMT 
Serum response factor binding protein 1 SRFBP1 
Lysyl oxidase LOX 
Zinc finger protein 474 ZNF474 
Synuclein- alpha interacting protein SNCAIP 
Cyclin G1CCNG1 
NudC domain containing 2 NUDCD2 
Hyaluronan-mediated motility receptor RHAMM 
Methionine adenosyltransferase II beta MAT2B 
Neuromedin U receptor 1 NMUR1 
5-hydroxytryptamine (serotonin) receptor 2BHTR2B 
Solute carrier family 39 (metal ion 
transporter)- member 11 
SLC39A11 
Sodium channel and clathrin linker 1 SCLT1 
Guanylate cyclase 1, soluble, alpha 2 GUCY1A2 
CWF19-like 2, cell cycle control (S. pombe) CWF19L2 
AlkB, alkylation repair homolog 8 (E. coli) ALKBH8 
ELMO/CED-12 domain containing 1 ELMOD1 
 
Table 3: List of genes found other suggestive regions after Meta-analysis 
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Figure 6: Regional plot of the most significant SNP on chromosome 9. The top SNP is 
represented by a purple diamond. The –log10 p-values are on the left y-axis and the right y-
axis shows the estimates rates of recombination. The SNP positions are on the x-axis, as 
well as the genes which flank a 400kb region.  The gene GRIN3A was the closest to the 
region associated with change in glucose due to HCTZ 
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Figure 7: Regional plot of the second SNP associated to change in glucose due to HCTZ. 
The SNP rs427576 on chromosome 16 is located in a gene desert. The top SNP is 
represented by a purple diamond. The –log10 p-values are on the left y-axis meanwhile the 
right y-axis shows the estimates rates of recombination. The SNP positions are on the x-axis 
as well as the genes which flank a 400kb region 
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Figure 8: Regional plot on chromosome 5. The MYO10 gene, which is located in the region, 
is related to the myosin heavy chain (MHC) gene family. These genes were linked to T2D
32
. 
The top SNP is represented by a purple diamond. The –log10 p-values are on the left y-axis 
and the right y-axis shows the estimates rates of recombination. The SNP positions are on 
the x-axis as well as the genes which flank a 400kb region 
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Figure 9: Regional plot of fourth most significant SNP on chromosome 6. This 
chromosomal location, 6q27 was previously reported in a Genome-Wide Meta-Analysis as 
associated with T1D
33
. The top SNP is represented by a purple diamond. The –log10 p-
values are on the left y-axis meanwhile the right y-axis shows the estimates rates of 
recombination. The SNP positions are on the x-axis as well as the genes which flank a 
400kb region 
 
 
 
 
 
 
 26 
 
 
 
 
 
 
 
 
 
 
Figure 10: Regional plot of chromosome 5 showing MGAT1 gene which has been 
previously associated with BMI, body weight and fatty acid metabolism
34, 35
The top SNP is 
represented by a purple diamond. The –log10 p-values are on the left y-axis and the right y-
axis shows the estimates rates of recombination. The SNP positions are on the x-axis as well 
as the genes which flank a 400kb region 
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Discussion 
 
In this study, we performed a meta-analysis of GWAS result from two non-Hispanic 
white pharmacogenetic studies consisting in total of over 425 individuals. We were not able 
to identify any locus which met the a prior defined genome-wide significance level for a 
GWAS for change in glucose level in response to HCZT treatment. However 50 SNPs in 9 
regions reached our criteria of suggestive association, and three of these regions were 
previously reported to be associated with relevant phenotypes in different GWA studies.  
HCTZ use has been suggested to be related to hyperglycemia in many clinical trials 
and observational studies, as well as a recent meta-analysis in comparison to other 
antihypertensive drugs
19
. I conclude that there are unlikely to be common SNPs with large 
effects on the adverse metabolic effects to hydrochlorothiazide treatment, and that large 
sample sizes will be needed for pharmacogenetic studies of inter-individual variation in 
response commonly prescribed medication. 
We observed suggestive evidence of association with change in glucose due to 
HCTZ for rs7702121. How the SNP rs7702121 may contribute to the change in glucose is 
unknown and the likelihood of this SNP being the causal variant is low. However this SNP 
is in high LD with the coding exon in MGAT1 which has been associated with body weight, 
BMI and fatty acid metabolism
34
. Mannosyl(alpha-1,3-)-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase (MGAT1) is an enzyme related to the synthesis of protein and 
lipids
36
. MGAT1 is a major contributor in the Monoacylglycerol pathway which produces 
Diacylglycerol (DAG)
37
. Elevated levels of DAG and increased activity of protein kinases C 
(PKC) are found in different tissues in diabetic individuals
38
.  Miele et al
39
 suggested that 
DAG regulates an important pathway in which glucose promotes the degradation of DAG as 
 28 
 
well as translocation of PKC from the plasma membrane to the cytoplasm. Removal of PKC 
activates the insulin receptor cascade leading to GLUT4 membrane translocation and 
glucose uptake
39
. Therefore I hypothesize that HCTZ modifies the activity of MGAT1 which 
will increase the production of DAG; avoiding, in this way, the capture of glucose by 
GLUT4 leading to an increase of plasma glucose in hypertensive individuals taking a 
diuretic. 
In another region, on chromosome 5, the SNP rs6870564 also showed suggestive 
evidence of association with change of in plasma glucose. This SNP is in close proximity to 
the MYO10 gene which codes an unconventional myosin
40
 that participates in different 
cellular processes such as membrane trafficking to signaling and cell motility. MYO10 may 
have a relationship with the pathogenesis of T2D as suggested by Olsson et al
32
. Contraction 
is a stimulant for the translocation of GLUT4 in skeletal muscle
32, 41
. Alteration in the 
expression of myosin in response to HCTZ may prevent the movement of GLUT4 to the 
plasma membrane of these cells which, in turn, would impede uptake of glucose into the cell 
and accumulation of glucose in blood. 
The last region to be discussed is on chromosome 6 where the SNP rs7762018 
reaches suggestive evidence of association to change in glucose due to HCTZ. The SNP was 
located in a 6q27 region which has been related to T1D in a genome-wide meta-analysis
33
 
and other autoimmune diseases
42
. 
It has been hypothesized that the mechanism by which HCTZ leads to 
hyperglycemia involves increased potassium excretion and hypokalemia.  It is interesting to 
note, therefore, that none of the genes identified to be suggestively associated with change in 
glucose were obviously related potassium transport or excretion
16
. Therefore, it is more 
 29 
 
likely that the mechanism involves a direct link with insulin sensitivity and metabolism as 
suggested by Eriksson et al.
22
  
In summary, the primary objective of this thesis was to identify genes or 
chromosomal regions that show an association with change in glucose levels in response to 
HCTZ in non-Hispanics whites.  Although we were not able to reach GWAS significant p-
values, 50 SNP in 9 regions had suggestive p-values. Large sample sizes and further meta-
analyses will be necessary to identify contributing to inter-individual variation in glucose 
response to HCTZ and likely other pharmacologic phenotypes. 
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APPENDIX 
 
Region Name chr Allele1 Allele2 Position Freq Allele1 Direction β P.value 
Region I 
rs10989824 9 T C 103907659 0.0599 -- -5.980 3.06E-06 
rs7034610 9 A G 103917056 0.0614 ++ 5.856 3.11E-06 
rs10820064 9 A T 103909080 0.0674 ++ 5.7556 3.99E-06 
rs10989829 9 A C 103909525 0.0674 ++ 5.7506 4.01E-06 
rs10989833 9 T G 103909860 0.0675 -- -5.743 4.02E-06 
rs10989837 9 T C 103910291 0.9324 ++ 5.731 4.07E-06 
rs10989791 9 A G 103857420 0.0592 ++ 5.8256 4.21E-06 
rs7020246 9 T G 103852964 0.9407 ++ 5.824 4.25E-06 
rs10760837 9 T C 103879660 0.059 -- -5.862 4.31E-06 
rs10760841 9 A G 103924080 0.939 -- -5.749 4.37E-06 
rs16921277 9 A G 103925122 0.939 -- -5.749 4.37E-06 
rs1449650 9 T G 103883859 0.0589 -- -5.860 4.45E-06 
rs10820051 9 T G 103884041 0.9411 ++ 5.86 4.47E-06 
rs10820055 9 T C 103897774 0.0589 -- -5.847 4.79E-06 
rs895989 9 T C 103898526 0.0588 -- -5.845 4.82E-06 
rs10760840 9 A G 103903001 0.0659 ++ 5.7746 4.92E-06 
rs10989820 9 T C 103901773 0.0588 -- -5.837 5.00E-06 
rs10820046 9 A G 103874453 0.9343 -- -5.722 5.24E-06 
rs1597340 9 T G 103957354 0.0616 -- -5.686 5.24E-06 
rs1449663 9 A G 103896314 0.9345 -- -5.698 6.13E-06 
rs10820076 9 T C 103943684 0.9323 ++ 5.570 6.23E-06 
rs10760846 9 T C 103944275 0.9323 ++ 5.567 6.28E-06 
Region II 
rs427576 16 A C 72386771 0.5617 -- -2.635 3.25E-06 
rs417278 16 T C 72387977 0.5811 ++ 2.622 4.58E-06 
rs379401 16 C G 72387865 0.587 -- -2.608 4.92E-06 
Region  
III 
A 
rs6870564 5 A G 17056085 0.1287 ++ 3.8521 3.28E-06 
rs11953330 5 T C 17059372 0.8716 ++ 3.846 3.39E-06 
rs11959796 5 A T 17059405 0.1285 ++ 3.8473 3.39E-06 
B 
rs7702121 5 A C 180131859 0.143 -- -3.783 5.09E-06 
rs6859974 5 T C 180138544 0.1436 ++ 3.731 5.63E-06 
rs1021001 5 C G 180136710 0.1435 -- -3.734 5.67E-06 
C 
rs890749 5 T C 121464495 0.809 -- -3.211 8.81E-06 
rs1834915 5 A T 121465418 0.1911 -- -3.210 8.82E-06 
rs2560322 5 C G 121467234 0.8087 ++ 3.2076 8.89E-06 
rs890750 5 T G 121463478 0.8098 -- -3.209 9.01E-06 
rs970041 5 A C 121467568 0.1924 -- -3.173 1.00E-05 
 31 
 
D rs2114997 5 A G 162584192 0.4274 -- -2.494 5.25E-06 
Region IV rs1669070 2 T C 231900549 0.4029 -- -3.032 3.82E-06 
Region V rs11077614 17 A G 68106224 0.5048 -- -3.188 4.12E-06 
Region VI 
rs7762018 6 A C 169855169 0.1319 ++ 3.703 4.59E-06 
rs6923339 6 A T 169869958 0.132 ++ 3.6979 4.73E-06 
rs6941766 6 A G 169873578 0.8679 -- -3.685 5.10E-06 
rs6904601 6 T G 169873830 0.8679 ++ 3.684 5.11E-06 
rs4716342 6 A G 169879884 0.8679 -- -3.683 5.15E-06 
rs1127489 6 T C 169849627 0.1292 -- -3.647 6.62E-06 
Region VII rs1551678 10 C G 127819002 0.3698 ++ 2.6746 6.91E-06 
Region 
VIII 
rs1974942 4 A G 129915671 0.1052 -- -5.089 8.69E-06 
Region IX 
rs7130701 11 A G 106699449 0.7894 -- -3.048 8.84E-06 
rs12274982 11 T C 106699749 0.2106 -- -3.047 8.89E-06 
rs4754214 11 A C 106692106 0.7894 -- -3.048 8.96E-06 
 
Table 4-Supplementary data: Top 50 SNPs associated with change of Glucose levels in 
Non-Hispanics white patients. These SNP were located in 9 genomic regions. In the case of 
chromosome 5, four different sub-regions were identified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Regional plots of 4 loci (chromosome 5, 17 and 2). These loci show suggestive association (p-values < 1 X 10-5) with change in glucose due to HCTZ. The top SNP is represented by a purple 
diamond. –log10 p-values are on the left y-axis meanwhile the right y-axis shows the estimates rates of recombination. The SNP positions are on the x-axis as well as the genes which flank a 400kb region 
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Figure 12: Regional plots of 3 loci (chromosome 10, 4 and 11). These loci show suggestive association (p-values < 1 X 10-5) with change in glucose due to HCTZ. The top SNP is represented by a 
purple diamond. –log10 p-values are on the left y-axis meanwhile the right y-axis shows the estimates rates of recombination. The SNP positions are on the x-axis as well as the genes which flank 
400kb region 
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